Do we Need New Therapies for Diabetes?
DOI:
https://doi.org/10.17140/DROJ-1-112Abstract
Diabetes research and practice cluster (drug developers, payers, regulators and physicians) often (and especially in recent times) question the need of new therapies. Why would we need new therapies nowadays, when we have 9 classes (insulins, sulfonylureas, biguanides, meglitdes, thiazolidnediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists),1 rapidly increasing number of biosimilars2 and uncountable number of generics? Reasonable question. Does it make sense to invest billions of dollars in messy global cardiovascular outcomes trials (as requested by diabetes drug development guidelines3) or to play love attraction games with payers4 so they “fall in love” with the “new” pill (most often combo with the good old metformin)?
Well….I believe someone is missing in this picture. Obviously, those four players forget the Patient. And the ability to ask a bit more simple and rational questions, such as “Do we have adequate glycemic control of diabetes in the presence of all those therapies”?
References
American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. 2015; 33(2): 97-111. doi: 10.2337/diaclin.33.2.97
Biosimilar insulins. Biosimilars-what you need to know? Diabetes News/Biosimilars-update/ 2014; Accessed 2015.
Shuren J. Guidance for industry diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: https://www.federalregister.gov/articles/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic 2008; Accessed 2015.
Mozeson M, Das N. The Pharma/Payer Relationship. The Pulse: The Wharton Health Care Journal.
Shuman J. Strategies for improved treatment adherence in type 2 diabetes. Available at: http://www.medpagetoday.com/resource-center/diabetes/Strategies-Improved-Treatment-Adherence-Type-2-Diabetes/a/31638 2012; Accessed 2015.
Stuart BC, Dai M, Xu J, E Loh FH, S Dougherty J. Does good medication 53(6): 517-523. doi: 10.1097/MLR.0000000000000360
Schmieder RE, Gitt AK, Koch C, et al. Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. BMC EndocrDisord
Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk.
ViaCyte. A service of the US National Institutes of Health. NCT02239354?term=viacyte&rank=1 2014; Accessed 2015.
Positive Diabetic Nephropathy Trial Results presented at ADA media/news-announcements 2015; Accessed 2015.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
